6-8 Bonhill Street
London EC2A 4BX
Full Time Employees:
|Mr. George Tziras||CEO & Non-Independent Director||275.48k||N/A||N/A|
|Mr. Peter David Rands||Chief Innovation & Intellectual Property Officer, Founder and Director||324.02k||N/A||N/A|
|Mr. David Steel||Chief Financial Officer||268.88k||N/A||N/A|
|Dr. Carol Routledge||Chief Scientific & Medical Officer||336.4k||N/A||N/A|
|Ms. Marie Claire Layzell||Chief Manufacturing & Devel. Officer & Director||317.82k||N/A||N/A|
|Dr. Alastair James Riddell M.D., M.Sc., MBChB, MFPM, MRCGP, MSc, Ph.D.||Chief Operating Officer||N/A||N/A||1949|
|Ms. Jenny Maguire||Head of Brand & Communications||N/A||N/A||N/A|
|Ms. Emma Hodge||Head of Intellectual Property||N/A||N/A||N/A|
|Mr. Richard M. Kimel HBA, LLB||Corp. Sec.||N/A||N/A||1967|
|Ms. Sarah Hamilton||Group Financial Controller||N/A||N/A||N/A|
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder. Its preclinical stage programs include SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801 oral formulation of 6-hydroxynorketamin. The company was incorporated in 2015 and is headquartered in London, the United Kingdom.
Small Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.